header background


EpiVax, Inc. uses computer modeling, gene sequencing and molecular immunology to develop new vaccines and predict and modify how drugs interact with a person’s immune system. The company uses bioinformatics and technology to design treatments and vaccines for smallpox, AIDS, tuberculosis, Type I diabetes, cancer and other diseases, and currently provides services in immunogenicity screening and testing in addition to its protein engineering and vaccine design expertise.